Related Experiment Video
Updated: May 20, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation
Oren Pasvolsky1, Curtis Marcoux2, Denái R Milton3
1Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Abstract:
Upfront autologous hematopoietic cell transplantation (autoHCT) remains standard of care for eligible patients with newly diagnosed multiple myeloma (MM). Comorbidities are routinely evaluated to determine eligibility and estimate mortality after autoHCT, including the history of prior solid tumor (PST). While PST is considered high-risk for worse survival based on widely used risk indices, its independent impact on transplant outcomes in MM remains unclear. To elucidate the prognostic impact of PST in patients with MM undergoing upfront autoHCT. We conducted a single-center retrospective analysis of consecutive MM patients who underwent upfront autoHCT between 1997 and 2021, categorizing them into those with (PST+) and without (PST-) prior solid organ malignancy. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Among 2853 patients included in this analysis, 274 (10%) were PST+ and 2579 (90%) were PST-. The PST+ patients were older (67 vs. 60 years; P < .001), predominantly male (66% vs. 58%; P = .010), were more often transplanted in the year 2010 or later (78% vs. 69%; P = .003) and were more likely to have high-risk cytogenetic abnormalities (30% vs. 24%; P = .06). There was no significant difference in pre-transplant hematologic response (P = .33), day-100 post-transplant (P = .35) or the best post-transplant response (P = .27) between the PST+ and PST- groups. Similarly, there were no differences in pre-transplant (P = .34) or best post-transplant (P = .44) MRD status between the two groups. After a median follow-up of 53.8 months (range 0.2-262), the median PFS was comparable (36.7 months in PST+ vs. 39.9 months in PST-, P = .31), yet the median OS was significantly shorter in the PST+ group (81.3 months vs. 104.0 months, P = .020). Multivariable analysis confirmed PST as an independent predictor of inferior OS (HR 1.34, P = .011). MM patients undergoing upfront autoHCT with PST had worse OS compared to those without PST, despite similar response rates and PFS.
More Related Videos
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

